Sight Sciences SEC filings document the company’s ophthalmic medical device business, segment operating results, governance, capital structure, and material events. Form 8-K filings report quarterly and annual financial results, investor presentation materials, and Regulation FD disclosures tied to the company’s Interventional Glaucoma and Interventional Dry Eye operations.
The filing record also includes definitive proxy materials for annual meeting matters, disclosures on executive officer changes and compensatory arrangements, material agreements such as lease amendments, and legal disclosures involving interventional glaucoma patents. These filings frame SGHT’s public reporting around product commercialization, intellectual property, corporate governance, risk factors, and shareholder voting matters.
Sight Sciences EVP of Operations & R&D Taylor Brenton reported a small open-market sale of company stock primarily to cover taxes on vesting equity. Brenton sold 2,829 shares of common stock at a weighted average price of $5.42 per share in multiple transactions.
The shares were sold to satisfy tax liabilities arising from the vesting of restricted stock units rather than as a discretionary portfolio move. After these sales, Brenton’s reported holdings total 264,978 shares, including 36,696 shares of common stock and 228,282 shares that will be received upon future RSU vesting and settlement.
Sight Sciences, Inc. Chief Operating Officer Alison Bauerlein reported an open-market sale of 24,184 shares of common stock at a weighted average price of $5.36 per share. According to the disclosure, the sale was made to cover her tax liability arising from the vesting of restricted stock units. After this transaction, she holds a total of 664,709 shares, including 192,669 shares of common stock and 472,040 shares subject to unvested restricted stock units that may be acquired upon future vesting and settlement.
Sight Sciences, Inc. President and CEO Paul Badawi reported an open-market sale of 28,684 shares of Common Stock at a weighted average price of $5.42 per share. According to the filing, the shares were sold to cover his tax liability arising from the vesting of restricted stock units (RSUs).
After this tax-related sale, Badawi holds a total of 6,122,472 shares, consisting of 5,572,746 shares of Common Stock and 549,726 additional shares that will be issued upon future vesting and settlement of unvested RSUs. The transaction represents only a small portion of his overall equity position.
Sight Sciences, Inc. (SGHT) is named as issuer in David Y. Badawi’s notice of a proposed sale of 7,418 common shares, with an aggregate market value of $40,857.60 and an approximate sale date of July 6, 2026. Badawi is identified as an officer and director. The shares were acquired from the issuer through restricted stock vesting on June 30, 2026. The proposed sale includes an amount needed to cover a tax obligation resulting from settlement of a vested equity award distribution.
Sight Sciences, Inc. (SGHT) officer Jeremy B. Hayden reported a planned sale of 12,733 common shares, with an aggregate market value of $70,132.10 and an approximate sale date of July 6, 2026. Hayden acquired 12,733 shares through restricted stock vesting on June 30, 2026. Joshua Schmitt signed as a duly authorized representative of Fidelity Brokerage Services LLC and attorney-in-fact for Jeremy Hayden.
SGHT filer submitted a Form 144 notice reporting proposed sale of 6,902 shares of Common Stock tied to Restricted Stock Vesting.
The filing lists shares outstanding 54,409,942 as of 07/02/2026 and discloses prior sales of 7,231 shares on 04/06/2026 with a reported value of $25,632.43. The filing identifies Fidelity Brokerage Services LLC as the broker.
Sight Sciences, Inc. officer Alison Bauerlein reported a proposed sale of 24,184 common shares, with an aggregate market value of $129,502.91 and an approximate sale date of July 2, 2026. The shares were acquired through restricted stock vesting on June 30, 2026. The sale includes an amount necessary to cover a tax obligation resulting from settlement of a vested equity award distribution.
During the prior three months, Bauerlein sold 25,874 shares on April 2, 2026, for gross proceeds of $90,007.90, and 12,728 shares on May 18, 2026, for gross proceeds of $65,129.18.
SGHT notice reports 2,829 shares of Common Stock listed under “Securities To Be Sold” tied to Restricted Stock Vesting with an event dated 06/30/2026. The filer entry lists a broker Fidelity Brokerage Services LLC and a filing reference date 07/01/2026.
SGHT submitted a Form 144 notice for the proposed sale of 28,684 shares of Common Stock tied to restricted stock vesting on 06/30/2026. The filing also records a prior sale by Paul Badawi of 29,244 shares on 04/01/2026 for $108,082.90. Shares outstanding were 54,409,942 as of 07/01/2026.
Sight Sciences director and 10% owner Staffan Encrantz reported an open-market purchase of 14,100 shares of Common Stock at a weighted average price of $4.879 per share. After this trade, he directly holds 1,434,283 shares, including 28,261 restricted stock units subject to vesting as previously reported.
He also reports indirect interests in 5,086,920 shares held by the 1997 Staffan Encrantz and Margareta Encrantz Revocable Trust, where he is a trustee, and 632,456 shares held by Allegro Investment Fund, L.P. He disclaims beneficial ownership of Allegro’s shares and of the trust and fund holdings beyond any pecuniary interest.